GemVax & KAEL

At a glance

GemVax & KAEL filed 144 disclosures in the last 12 months, including 21 insider, 18 5% holder, 6 issuance, 1 buyback and 1 m&a. The most recent key filing was on Oct 26: A major holder's stake rose from 24.81% to 24.94% (related-party change).

Revenue for 2025 was ₩81.5B, up 30.1% on 2024. Operating margin was 4.7% against -61.2% a year earlier. The latest interim report (2026 H1) shows revenue of ₩41B and operating profit of ₩232.5M.

The 2025 annual report lists 217 employees with an average tenure of 7.1 years and average pay of ₩46.9M, #1590 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩149M each on average. It paid no cash dividend for 2025. ㈜젬앤컴퍼니 and related parties held 25.92% at year end.

Of 1 recent 5%+ holder report, 1 raised and 0 cut a stake; the largest stake reported was 24.94% on Oct 26.

From the 2025 annual report

Staff: 217 (151 men, 66 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩10.3B. Directors and auditors: 7, paid ₩1B in total.

No cash dividend was paid for 2025.

Largest shareholder

㈜젬앤컴퍼니 holds 10.51%; with 16 related parties the group holds 25.92% of common shares at year end (from 28.56% at the start of the year).

Auditor: 한울 회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports